Clinical Features, Cardiac 11C-HED Retention Measures, and 11C-DTBZ Binding to Posterior Putamen in Patients with Neurodegenerative Diseases
| Intensity of* | Mean ± SD 11C-HED RI (mL of blood/min/mL of tissue) | Extent of 11C-HED retention deficit (%)† | 11C-DTBZ posterior putamen BP (unitless)‡ | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Patient | Sex | Age (y) | Park | Atax | Auto | Entire LV | LCX | LAD | RCA | ||
| IPD | 1 | M | 69 | ++ | − | − | 0.025 ± 0.003 | 97 | 100 | 95 | 100 | 0.61 |
| 2 | M | 46 | + | − | − | 0.086 ± 0.020 | — | — | — | — | 0.40 | |
| 3 | M | 77 | + | − | − | 0.022 ± 0.004 | 100 | 100 | 100 | 100 | 0.68 | |
| 4 | M | 73 | + | − | − | 0.078 ± 0.009 | — | — | — | — | 0.49 | |
| 5 | M | 35 | + | − | − | 0.071 ± 0.011 | — | — | — | — | 0.72 | |
| 6 | M | 75 | ++ | − | − | 0.026 ± 0.003 | 97 | 100 | 96 | 100 | 0.68 | |
| 7 | F | 65 | + | − | − | 0.075 ± 0.011 | — | — | — | — | 0.71 | |
| 8 | M | 47 | ++ | − | + | 0.076 ± 0.010 | — | — | — | — | 0.38 | |
| 9 | M | 72 | ++ | − | − | 0.023 ± 0.003 | 96 | 100 | 93 | 100 | 0.73 | |
| MSA | 1 | M | 70 | +++ | − | +++ | 0.027 ± 0.004 | 92 | 100 | 87 | 100 | 0.72 |
| 2 | M | 59 | +++ | ++ | +++ | 0.026 ± 0.004 | 97 | 100 | 95 | 100 | 0.49 | |
| 3 | F | 77 | +++ | +++ | ++ | 0.089 ± 0.014 | — | — | — | — | 1.70 | |
| 4 | M | 62 | + | +++ | ++ | 0.073 ± 0.007 | — | — | — | — | 0.54 | |
| 5 | M | 60 | +++ | +++ | +++ | 0.061 ± 0.008 | 2 | 8 | — | — | 0.52 | |
| 6 | M | 57 | + | ++ | ++ | 0.084 ± 0.009 | — | — | — | — | 2.47 | |
| 7 | F | 61 | − | +++ | +++ | 0.070 ± 0.008 | — | — | — | — | 0.79 | |
| 8 | F | 59 | +++ | +++ | +++ | 0.057 ± 0.009 | 23 | 71 | 2 | 38 | 0.76 | |
| 9 | M | 63 | ++ | +++ | +++ | 0.077 ± 0.011 | — | — | — | — | 2.27 | |
| 10 | M | 53 | + | +++ | +++ | 0.053 ± 0.006 | 21 | 32 | 5 | 71 | 2.34 | |
| PSP | 1 | F | 68 | +++ | − | − | 0.088 ± 0.008 | — | — | — | — | 0.86 |
| 2 | F | 78 | + | − | − | 0.078 ± 0.013 | — | — | — | — | 2.01 | |
| 3 | M | 63 | ++ | − | − | 0.036 ± 0.008 | 81 | 95 | 72 | 100 | 0.34 | |
| 4 | F | 71 | ++ | − | − | 0.041 ± 0.009 | 66 | 100 | 49 | 100 | 0.56 | |
| 5 | F | 67 | ++ | − | − | 0.077 ± 0.013 | — | — | — | — | 1.06 | |
| 6 | F | 80 | ++ | − | − | 0.082 ± 0.014 | 1 | — | 1 | — | 0.51 | |
| 7 | F | 72 | ++ | − | − | 0.077 ± 0.017 | — | — | — | — | 0.92 | |
| 8 | M | 69 | + | − | ++ | 0.073 ± 0.015 | — | — | — | — | 0.53 | |
↵* Park = intensity of parkinsonian symptoms of akinesia, rigidity, tremor at rest, and hypokinetic speech; Atax = intensity of ataxia of gait, limbs, and speech; Auto = intensity of orthostatic blood pressure and pulse changes and urinary incontinence. Rating scale: – = normal; + = mild; ++ = moderate; +++ = marked.
↵† For patients with no regions of abnormal 11C-HED retention, extent measures of 0% are represented by dash. Entire LV = fractional area of entire left ventricle (LV) that is denervated. Fractional areas of denervation in 3 coronary arteries (LCX, LAD, and RCA) are also given.
↵‡ 11C-DTBZ binding potential (BP) in posterior putamen was calculated from measured DVR as BP = DVR – 1; in healthy control subjects, mean ± SD was 2.52 ± 0.32.